AR097078A1 - Combinaciones que comprenden compuestos maba y corticosteroides, uso, kit y compuesto - Google Patents

Combinaciones que comprenden compuestos maba y corticosteroides, uso, kit y compuesto

Info

Publication number
AR097078A1
AR097078A1 ARP140102788A ARP140102788A AR097078A1 AR 097078 A1 AR097078 A1 AR 097078A1 AR P140102788 A ARP140102788 A AR P140102788A AR P140102788 A ARP140102788 A AR P140102788A AR 097078 A1 AR097078 A1 AR 097078A1
Authority
AR
Argentina
Prior art keywords
hydroxy
corticosteroid
inhibitors
compound
maba
Prior art date
Application number
ARP140102788A
Other languages
English (en)
Inventor
Gavalda Monedero Amadeu
Aparici Virgili Monica
Calbet Murtro Marta
Miralpeix Guell Montserrat
Puig Duran Carlos
Original Assignee
Almirall Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almirall Sa filed Critical Almirall Sa
Publication of AR097078A1 publication Critical patent/AR097078A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Reivindicación 1: Una combinación que comprende (a) un corticosteroide y (b) un compuesto dual antagonista muscarínico - agonista b2 adrenérgico que es hidroxi(di-2-tienil)acetato de trans-4-[{3-[5-({[(2R)-2-hidroxi-2-(8-hidroxi-2-oxo-1,2-dihidroquinolin-5-iI)etil]amino}metil)-1H-1,2,3-benzotriazoI-1-iI]propil}(metil)amino]ciclohexilo, o cualquier sal o solvato farmacéuticamente aceptable del mismo. Reivindicación 3: Una combinación según la reivindicación 1 ó 2, en donde el corticosteroide seselecciona del grupo que comprende budesonida, dipropionato de beclometasona, triamcinolona, furoato de mometasona, ciclesonida, propionato de fluticasona y furoato de fluticasona. Reivindicación 10: Una combinación según una cualquiera de las reivindicaciones precedentes, que comprende además (c) otro compuesto activo seleccionado de: (i) inhibidores de PDE IV, (ii) antagonistas de Ieucotrieno D4, (iii) inhibidores de egfr-quinasa, (iv) inhibidores de quinasa p38, (v) inhibidores de JAK y (vi) agonistas del receptor NK1.
ARP140102788A 2013-07-25 2014-07-25 Combinaciones que comprenden compuestos maba y corticosteroides, uso, kit y compuesto AR097078A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13382305 2013-07-25

Publications (1)

Publication Number Publication Date
AR097078A1 true AR097078A1 (es) 2016-02-17

Family

ID=48917475

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140102788A AR097078A1 (es) 2013-07-25 2014-07-25 Combinaciones que comprenden compuestos maba y corticosteroides, uso, kit y compuesto

Country Status (9)

Country Link
US (1) US10456390B2 (es)
EP (1) EP3024459B1 (es)
JP (1) JP6501774B2 (es)
CN (1) CN105407890B (es)
AR (1) AR097078A1 (es)
ES (1) ES2727526T3 (es)
TW (1) TW201517906A (es)
UY (1) UY35677A (es)
WO (1) WO2015011245A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
BR112015013628A2 (pt) 2012-12-18 2017-07-11 Almirall Sa derivados de carbamato de ciclo-hexila e quinuclidinila tendo atividades agonista adrenérgica de beta2 e antagonista muscarínica de m3
TWI643853B (zh) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
TWI641373B (zh) 2013-07-25 2018-11-21 阿爾米雷爾有限公司 具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽
TW201517906A (zh) 2013-07-25 2015-05-16 Almirall Sa 含有ｍａｂａ化合物和皮質類固醇之組合
TW201617343A (zh) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物
WO2019076997A1 (en) 2017-10-20 2019-04-25 Chiesi Farmaceutici S.P.A. PHARMACEUTICAL FORMULATIONS COMPRISING AN OPIOID RECEPTOR AGONIST AS ACTIVE SUBSTANCES, METHODS OF MAKING THEM AND THERAPEUTIC USES THEREOF
CN113544121A (zh) * 2019-06-06 2021-10-22 中国医药研究开发中心有限公司 具有β2受体激动及M受体拮抗活性的杂环衍生物及其医药用途
CN110169969B (zh) * 2019-06-28 2022-05-27 南京医科大学 Mk571在制备预防和治疗心脏病药物中应用

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1212742B (it) 1983-05-17 1989-11-30 Dompe Farmaceutici Spa Derivati dibenzo [1,4]diazepinonici pirido [1,4] benzodiazepinonici,pirido [1,5] benzodiazepinonici e loro attivita' farmacologica
DE3370320D1 (en) 1983-09-26 1987-04-23 Magis Farmaceutici Aminocyclohexanol derivatives having an expectorant activity, process for their preparation and pharmaceutical compositions containing them
EP0416925A3 (en) 1989-09-07 1991-09-25 Glaxo Group Limited Use of 4-hydroxy-alpha 1-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-1,3-benzenedimethanol or its salts in the treatment of allergy and inflammation
GB9020051D0 (en) 1990-09-13 1990-10-24 Pfizer Ltd Muscarinic receptor antagonists
EP0923536A1 (en) 1996-07-29 1999-06-23 Pharmacia & Upjohn Aktiebolag Arylcycloalkane carboxylic esters, their use, pharmaceutical compositions and preparation
WO1998009632A1 (en) 1996-09-06 1998-03-12 Merck & Co., Inc. Methods and compositions for treating preterm labor
SE9704644D0 (sv) 1997-12-12 1997-12-12 Astra Ab New use
EP1107738A4 (en) * 1998-08-27 2003-01-22 Bristol Myers Squibb Co Novel pharmaceutical salt form
US6673908B1 (en) 1999-02-22 2004-01-06 Nuvelo, Inc. Tumor necrosis factor receptor 2
PT1204643E (pt) 1999-08-20 2008-09-15 Dow Agrosciences Llc Amidas aromáticas heterocíclicas fungicidas e suas composições, métodos de utilização e preparação
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
WO2004089892A2 (en) 2003-04-01 2004-10-21 Theravance, Inc. Diarylmethyl and related compounds having beta2 andrenergic receptor agonist and muscarinic receptor antagonist activity
JP4616264B2 (ja) 2003-05-28 2011-01-19 セラヴァンス， インコーポレーテッド ムスカリン性レセプターアンタゴニストとしてのアザビシクロアルカン化合物
US7320990B2 (en) 2004-02-13 2008-01-22 Theravance, Inc. Crystalline form of a biphenyl compound
DE102004024453A1 (de) 2004-05-14 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Bronchodilatoren zur Behandlung von Atemwegserkrankungen
ES2251867B1 (es) 2004-06-21 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
US7528253B2 (en) 2004-08-16 2009-05-05 Theravance, Inc. Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity
WO2006023460A2 (en) 2004-08-16 2006-03-02 Theravance, Inc. COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
TWI374883B (en) 2004-08-16 2012-10-21 Theravance Inc Crystalline form of a biphenyl compound
BRPI0614290A2 (pt) 2005-08-08 2011-03-22 Argenta Discovery Ltd derivados de biciclo [ 2.2.1 ] hept-7-ilamina e seus usos
BRPI0617674A2 (pt) * 2005-10-19 2011-08-02 Ranbaxy Lab Ltd composições farmacêuticas e seus usos
GB0602778D0 (en) 2006-02-10 2006-03-22 Glaxo Group Ltd Novel compound
NZ570693A (en) 2006-03-20 2011-02-25 Pfizer Ltd Amine derivatives
GB0613154D0 (en) 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
GB0702384D0 (en) 2007-02-07 2007-03-21 Argenta Discovery Ltd Chemical compounds
WO2008017827A2 (en) 2006-08-08 2008-02-14 Argenta Discovery Limited Azole and thiazole derivatives and their uses
EP1894568A1 (en) * 2006-08-31 2008-03-05 Novartis AG Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases
AU2007303909A1 (en) 2006-10-04 2008-04-10 Pfizer Limited Sulfonamide derivatives as adrenergic agonists and muscarinic antagonists
TW200825084A (en) 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
GB0700972D0 (en) 2007-01-18 2007-02-28 Imp Innovations Ltd Treatment of inflammatory disease
WO2008096129A1 (en) 2007-02-07 2008-08-14 Argenta Discovery Ltd Nitrogen containing hetrocyclic compounds useful as bifunctional modulators of m3 receptors and beta- 2 receptors
GB0702413D0 (en) 2007-02-07 2007-03-21 Argenta Discovery Ltd New chemical compounds
WO2008149110A1 (en) 2007-06-08 2008-12-11 Argenta Discovery Limited Bicyclor [2.2.1] hept-7-ylamine derivatives and their use in the treatment of diseases and conditions in which m3 muscarinic receptor activity and beta-adrenergic activity are implicated
PE20090907A1 (es) 2007-07-21 2009-08-05 Boehringer Ingelheim Int Nuevos medicamentos pulverulentos que contienen tiotropio y salmeterol, asi como lactosa como excipiente
WO2009017813A1 (en) 2007-08-02 2009-02-05 Teva Pharmaceutical Industries Ltd. O-desmethyl venlafaxine saccharinate
NZ586872A (en) 2008-02-06 2012-03-30 Astrazeneca Ab Spirocyclic amide compounds
CN101544572B (zh) 2008-03-26 2013-03-20 连云港恒邦医药科技有限公司 一种氨溴索衍生物及其制备方法
KR100990872B1 (ko) 2008-05-06 2010-10-29 한국화학연구원 신규한 1-페닐-카르복실산 에스테르 유도체 또는 이의약학적으로 허용가능한 염, 이의 제조방법 및 이를유효성분으로 함유하는 무스카린 수용체 길항제 또는유기인 화합물 중독에 의한 신경계 질환 예방 및 치료용약학적 조성물
GB0808708D0 (en) 2008-05-13 2008-06-18 Astrazeneca Ab New compounds 274
CN102131505A (zh) 2008-06-20 2011-07-20 阿斯利康(瑞典)有限公司 用于调节β2-肾上腺素受体活性的包含4-羟基-2-氧代-2，3-二氢-1，3-苯并噻唑-7-基化合物的药物组合物
US8263623B2 (en) 2008-07-11 2012-09-11 Pfizer Inc. Triazol derivatives useful for the treatment of diseases
US20100272811A1 (en) * 2008-07-23 2010-10-28 Alkermes,Inc. Complex of trospium and pharmaceutical compositions thereof
WO2010015792A1 (en) 2008-08-06 2010-02-11 Argenta Discovery Limited Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors
EP2196465A1 (en) 2008-12-15 2010-06-16 Almirall, S.A. (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors
PL3210981T3 (pl) 2009-04-23 2019-06-28 Theravance Respiratory Company, Llc Związki diamidowe wykazujące działanie jako antagonista receptora muskarynowego i agonista antagonista receptora beta 2 adrenergicznego
EP2426121A4 (en) 2009-04-30 2012-10-31 Teijin Pharma Ltd QUARTER AMMONIUM SALT CONNECTION
GB0913345D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab New combination 802
GB201002612D0 (en) 2010-02-16 2010-03-31 Jagotec Ag Improvements in or relating to organic compounds
ITRM20110083U1 (it) 2010-05-13 2011-11-14 De La Cruz Jose Antonio Freire Piastra per la costruzione di carrelli per aeroplani
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
AR083115A1 (es) 2010-09-30 2013-01-30 Theravance Inc Sales oxalato cristalinas de un compuesto diamida
GB201021992D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab Compound
GB201021979D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab New compound
KR101906630B1 (ko) 2011-06-10 2018-10-10 키에시 파르마슈티시 엣스. 피. 에이. 무스카린 수용체 길항제 및 베타2 아드레날린 수용체 작용제 효능을 갖는 화합물
PT2718280E (pt) 2011-06-10 2015-11-25 Chiesi Farma Spa Compostos possuindo uma atividade antagonista de um recetor muscarínico e agonista de um recetor beta2 adrenérgico
PE20161219A1 (es) 2011-11-11 2016-11-17 Pfizer 2-tiopirimidinonas
MX2020000331A (es) 2011-11-11 2022-03-16 Gilead Apollo Llc Inhibidores de acetil coa carboxilasa (acc) y usos de los mismos.
EP2592077A1 (en) * 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
EP2592078A1 (en) * 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
UA116622C2 (uk) 2011-11-11 2018-04-25 Аллерган, Інк. Похідні 4-прегенен-11ss-17-21-тріол-3,20-діону для лікування хвороб очей
TW201427977A (zh) 2012-12-06 2014-07-16 Chiesi Farma Spa 具有蕈毒鹼受體拮抗劑及β２腎上腺素受體致效劑活性之化合物
HUE037944T2 (hu) 2012-12-06 2018-09-28 Chiesi Farm Spa Muszkarin receptor antagonista és béta2 adrenerg receptor agonista akitvitással rendelkezõ vegyületek
BR112015013628A2 (pt) 2012-12-18 2017-07-11 Almirall Sa derivados de carbamato de ciclo-hexila e quinuclidinila tendo atividades agonista adrenérgica de beta2 e antagonista muscarínica de m3
EP3388441A1 (en) 2012-12-18 2018-10-17 Vertex Pharmaceuticals Incorporated Mannose derivatives for treating bacterial infections
RS58129B1 (sr) 2012-12-18 2019-02-28 Chiesi Farm Spa Derivati 3-okso-2,3,5,8-tetrahidro-[1,2,4]triazolo[4,3-a]pirimidina za tretman respiratornih bolesti
TWI643853B (zh) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
TW201440768A (zh) 2013-02-27 2014-11-01 Almirall Sa 雙毒蕈鹼拮抗劑-β2腎上腺素促效劑複合物及皮質類固醇之組合物
TW201517906A (zh) 2013-07-25 2015-05-16 Almirall Sa 含有ｍａｂａ化合物和皮質類固醇之組合
TWI641373B (zh) 2013-07-25 2018-11-21 阿爾米雷爾有限公司 具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽
GB201317363D0 (en) 2013-10-01 2013-11-13 Eisai Ltd Novel compounds
TW201617343A (zh) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物

Also Published As

Publication number Publication date
JP6501774B2 (ja) 2019-04-17
CN105407890A (zh) 2016-03-16
UY35677A (es) 2015-02-27
EP3024459A1 (en) 2016-06-01
CN105407890B (zh) 2019-06-07
JP2016527245A (ja) 2016-09-08
TW201517906A (zh) 2015-05-16
WO2015011245A1 (en) 2015-01-29
EP3024459B1 (en) 2019-03-27
US10456390B2 (en) 2019-10-29
US20160175295A1 (en) 2016-06-23
ES2727526T3 (es) 2019-10-16

Similar Documents

Publication Publication Date Title
AR097078A1 (es) Combinaciones que comprenden compuestos maba y corticosteroides, uso, kit y compuesto
PH12018501807A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of diseas
DOP2019000117A (es) Nuevos derivados de quinolina
BR112017007662A8 (pt) Composto, composição farmacêutica e uso de um composto
CR20170563A (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso.
BR112016030733A2 (pt) Derivados de indano e indolina e uso dos mesmos como ativadores de guanilato ciclase solúveis
BR112015020302A2 (pt) derivado de pirazol
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
CR20170411A (es) Composiciones farmacéuticas que comprenden n-(3,5-dimetoxifenil)-n-(1-metiletil)-n-[3-(1-metil-1h-pirazol-4-il-quin oxalin-6-il]etano-1,2-diamina
CO2019014484A2 (es) Nuevos derivados de azaquinolina
DOP2014000059A (es) Derivados de estra–1,3,5(10),16–tetraen–3–carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
BR112017016817A2 (pt) derivados heterocíclicos formilados como inibidores de fgfr4
BR112015019587A2 (pt) combinações compreendendo compostos maba e corticosteroides
CL2020002891A1 (es) Nuevos derivados de quinolina
AR086800A1 (es) Composicion farmaceutica oftalmologica topica que contiene regorafenib
WO2015116856A3 (en) Farnesoid x receptor antagonists
UY37837A (es) Nuevos compuestos heterocíclicos como inhibidores de cdk8/19
BR112016026552A8 (pt) derivados de carboxamida, seus usos, composição farmacêutica, e combinação
EA201990765A1 (ru) Азаиндазольные соединения для применения при повреждениях сухожилий и/или связок
BR112017021583A2 (pt) métodos para o tratamento de transtornos inflamatórios
BR112018073419A2 (pt) combinação, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica
MY196425A (en) Indazole Compounds For Use In Tendon And/Or Ligament Injuries
BR112018073410A2 (pt) combinação de antagonistas, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica
PE20130813A1 (es) Nueva asociacion entre la 4-{3-[cis-hexahidrociclopenta[c]pirrol-2(1h)-il]propoxi}benzamida y un antagonista de los receptores nmda y las composiciones farmaceuticas que la contienen
BR112018073396A2 (pt) combinação de antagonistas, uso de uma combinação, método para o tratamento de desordens cognitivas, composto, método para o tratamento de doença de alzheimer e composição farmacêutica

Legal Events

Date Code Title Description
FB Suspension of granting procedure